法律人 LawPlayer logo

資料由法律人 LawPlayer整理提供·EU law / curated by LawPlayer from EUR-Lex

Regulation

Commission Implementing Regulation (EU) 2018/917 of 27 June 2018 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, carvone, chlorpropham, cyazofamid, desmedipham, dimethoate, dimethomorph, diquat, ethephon, ethoprophos, etoxazole, famoxadone, fenamidone, fenamiphos, flumioxazine, fluoxastrobin, folpet, foramsulfuron, formetanate, Gliocladium catenulatum strain: J1446, isoxaflutole, metalaxyl-m, methiocarb, methoxyfenozide, metribuzin, milbemectin, oxasulfuron, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole, pymetrozine and s-metolachlor (Text with EEA relevance.)

CELEX
Implementing Regulation (EU) 2018/917
Date of document
Articles
3
Source
EUR-Lex
Article 1

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 15, Diquat, the date is replaced by ‘30 June 2019’;

(2)

in the sixth column, expiration of approval, of row 23, Pymetrozine, the date is replaced by ‘30 June 2019’;

(3)

in the sixth column, expiration of approval, of row 35, Famoxadone, the date is replaced by ‘30 June 2019’;

(4)

in the sixth column, expiration of approval, of row 37, Metalaxyl-M, the date is replaced by ‘30 June 2019’;

(5)

in the sixth column, expiration of approval, of row 39, Flumioxazine, the date is replaced by ‘30 June 2019’;

(6)

in the sixth column, expiration of approval, of row 42, Oxasulfuron, the date is replaced by ‘31 July 2019’;

(7)

in the sixth column, expiration of approval, of row 44, Foramsulfuron, the date is replaced by ‘31 July 2019’;

(8)

in the sixth column, expiration of approval, of row 46, Cyazofamid, the date is replaced by ‘31 July 2019’;

(9)

in the sixth column, expiration of approval, of row 62, Fenamidone, the date is replaced by ‘31 July 2019’;

(10)

in the sixth column, expiration of approval, of row 63, Isoxaflutole, the date is replaced by ‘31 July 2019’;

(11)

in the sixth column, expiration of approval, of row 78, Chlorpropham, the date is replaced by ‘31 July 2019’;

(12)

in the sixth column, expiration of approval, of row 83, Alpha-cypermethrin, the date is replaced by ‘31 July 2019’;

(13)

in the sixth column, expiration of approval, of row 84, Benalaxyl, the date is replaced by ‘31 July 2019’;

(14)

in the sixth column, expiration of approval, of row 85, Bromoxynil, the date is replaced by ‘31 July 2019’;

(15)

in the sixth column, expiration of approval, of row 86, Desmedipham, the date is replaced by ‘31 July 2019’;

(16)

in the sixth column, expiration of approval, of row 88, Phenmedipham, the date is replaced by ‘31 July 2019’;

(17)

in the sixth column, expiration of approval, of row 96, Methoxyfenozide, the date is replaced by ‘31 July 2019’;

(18)

in the sixth column, expiration of approval, of row 97, S-metolachlor, the date is replaced by ‘31 July 2019’;

(19)

in the sixth column, expiration of approval, of row 98, Gliocladium catenulatum strain: J1446, the date is replaced by ‘31 July 2019’;

(20)

in the sixth column, expiration of approval, of row 99, Etoxazole, the date is replaced by ‘31 July 2019’;

(21)

in the sixth column, expiration of approval, of row 109, Bifenazate, the date is replaced by ‘31 July 2019’;

(22)

in the sixth column, expiration of approval, of row 110, Milbemectin, the date is replaced by ‘31 July 2019’;

(23)

in the sixth column, expiration of approval, of row 141, Fenamiphos, the date is replaced by ‘31 July 2019’;

(24)

in the sixth column, expiration of approval, of row 142, Ethephon, the date is replaced by ‘31 July 2019’;

(25)

in the sixth column, expiration of approval, of row 145, Captan, the date is replaced by ‘31 July 2019’;

(26)

in the sixth column, expiration of approval, of row 146, Folpet, the date is replaced by ‘31 July 2019’;

(27)

in the sixth column, expiration of approval, of row 147, Formetanate, the date is replaced by ‘31 July 2019’;

(28)

in the sixth column, expiration of approval, of row 148, Methiocarb, the date is replaced by ‘31 July 2019’;

(29)

in the sixth column, expiration of approval, of row 149, Dimethoate, the date is replaced by ‘31 July 2019’;

(30)

in the sixth column, expiration of approval, of row 150, Dimethomorph, the date is replaced by ‘31 July 2019’;

(31)

in the sixth column, expiration of approval, of row 152, Metribuzin, the date is replaced by ‘31 July 2019’;

(32)

in the sixth column, expiration of approval, of row 153, Phosmet, the date is replaced by ‘31 July 2019’;

(33)

in the sixth column, expiration of approval, of row 154, Propamocarb, the date is replaced by ‘31 July 2019’;

(34)

in the sixth column, expiration of approval, of row 155, ethoprophos, the date is replaced by ‘31 July 2019’;

(35)

in the sixth column, expiration of approval, of row 156, Pirimiphos-methyl, the date is replaced by ‘31 July 2019’;

(36)

in the sixth column, expiration of approval, of row 158, Beflubutamid, the date is replaced by ‘31 July 2019’;

(37)

in the sixth column, expiration of approval, of row 163, Benthiavalicarb, the date is replaced by ‘31 July 2019’;

(38)

in the sixth column, expiration of approval, of row 164, Boscalid, the date is replaced by ‘31 July 2019’;

(39)

in the sixth column, expiration of approval, of row 165, Carvone, the date is replaced by ‘31 July 2019’;

(40)

in the sixth column, expiration of approval, of row 166, Fluoxastrobin, the date is replaced by ‘31 July 2019’;

(41)

in the sixth column, expiration of approval, of row 167, Paecilomyces lilacinus strain 251, the date is replaced by ‘31 July 2019’;

(42)

in the sixth column, expiration of approval, of row 168, Prothioconazole, the date is replaced by ‘31 July 2019’.

3 articles

Cite this act

Commission Implementing Regulation (EU) 2018/917 of 27 June 2018 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, carvone, chlorpropham, cyazofamid, desmedipham, dimethoate, dimethomorph, diquat, ethephon, ethoprophos, etoxazole, famoxadone, fenamidone, fenamiphos, flumioxazine, fluoxastrobin, folpet, foramsulfuron, formetanate, Gliocladium catenulatum strain: J1446, isoxaflutole, metalaxyl-m, methiocarb, methoxyfenozide, metribuzin, milbemectin, oxasulfuron, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole, pymetrozine and s-metolachlor (Text with EEA relevance.) (EUR-Lex). Retrieved via LawPlayer, https://lawplayer.com/eu/act/32018R0917

© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.

EU-EurLex-Reuse-2011-833

本頁資料來源:EUR-Lex·整理提供:法律人 LawPlayer· lawplayer.com